Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

3-30-2022

Computationally driven discovery of SARS-CoV-2 M pro inhibitors:
From design to experimental validation
Léa El Khoury
Incubateur Paris Biotech Santé

Jay W Ponder
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
El Khoury, Léa; Ponder, Jay W; and et al, "Computationally driven discovery of SARS-CoV-2 M pro
inhibitors: From design to experimental validation." Chemical Science. 13, 13. 3674 - 3687. (2022).
https://digitalcommons.wustl.edu/oa_4/262

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Showcasing research from Professor Piquemal’s laboratory,
Department of Chemistry, Sorbonne Université, Paris, France and
from Qubit Pharmaceuticals, Paris, France.

As featured in:

Computationally driven discovery of SARS-CoV-2 Mpro inhibitors:
from design to experimental validation
We report a fast-track computationally driven discovery of new
SARS-CoV-2 main protease (Mpro) inhibitors whose potency ranges
from mM for the initial non-covalent ligands to sub-μM for the ﬁnal
covalent compound (IC50 = 830 ± 50 nM). The project extensively
relied on high-resolution all-atom molecular dynamics simulations
and absolute binding free energy calculations performed using
the polarizable AMOEBA force ﬁeld. While simulations extensively
use high performance computing to strongly reduce the time-tosolution, they were systematically coupled to nuclear magnetic
resonance experiments to drive synthesis and for in vitro
characterization of compounds.

See Jean-Philip Piquemal,
Davide Sabbadin et al.,
Chem. Sci., 2022, 13, 3674.

rsc.li/chemical-science
Registered charity number: 207890

Chemical
Science
View Article Online

Open Access Article. Published on 10 February 2022. Downloaded on 9/16/2022 7:13:52 PM.
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.

EDGE ARTICLE

Cite this: Chem. Sci., 2022, 13, 3674
All publication charges for this article
have been paid for by the Royal Society
of Chemistry

View Journal | View Issue

Computationally driven discovery of SARS-CoV-2
Mpro inhibitors: from design to experimental
validation†‡
Léa El Khoury, §a Zhifeng Jing, §a Alberto Cuzzolin,b Alessandro Deplano,c
Daniele Loco,a Boris Sattarov,a Florent Hédin, a Sebastian Wendeborn,d Chris Ho,a
Dina El Ahdab, n Theo Jaﬀrelot Inizan,n Mattia Sturlese,g Alice Sosic,e
Martina Volpiana,e Angela Lugato,e Marco Barone,e Barbara Gatto,e
Maria Ludovica Macchia,e Massimo Bellanda,f Roberto Battistutta,f
Cristiano Salata, h Ivan Kondratov,i Rustam Iminov,i Andrii Khairulin,i
Yaroslav Mykhalonok,i Anton Pochepko,i Volodymyr Chashka-Ratushnyi,i
Iaroslava Kos,i Stefano Moro, g Matthieu Montes,j Pengyu Ren,k Jay W. Ponder, lm
Louis Lagardère,n Jean-Philip Piquemal *no and Davide Sabbadin*a
We report a fast-track computationally driven discovery of new SARS-CoV-2 main protease (Mpro) inhibitors
whose potency ranges from mM for the initial non-covalent ligands to sub-mM for the ﬁnal covalent
compound (IC50 ¼ 830  50 nM). The project extensively relied on high-resolution all-atom molecular
dynamics simulations and absolute binding free energy calculations performed using the polarizable
AMOEBA force ﬁeld. The study is complemented by extensive adaptive sampling simulations that are
used to rationalize the diﬀerent ligand binding poses through the explicit reconstruction of the ligand–
protein conformation space. Machine learning predictions are also performed to predict selected
compound properties. While simulations extensively use high performance computing to strongly
reduce the time-to-solution, they were systematically coupled to nuclear magnetic resonance
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experiments to drive synthesis and for in vitro characterization of compounds. Such a study highlights
the power of in silico strategies that rely on structure-based approaches for drug design and allows the
protein conformational multiplicity problem to be addressed. The proposed ﬂuorinated
tetrahydroquinolines open routes for further optimization of Mpro inhibitors towards low nM aﬃnities.

1. Introduction
Since December 2019, the COVID-19 global pandemic has put the
entire world on edge.1,2 The disease is due to a coronavirus (CoV)

called SARS-CoV-2 (severe acute respiratory syndrome, SARS) that
has triggered the start of an unprecedented research eﬀort.3–5
While the vaccination strategy6 has been particularly successful
with the rise of mRNA techniques, additional programs have
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Paris, France. E-mail: jean-philip.piquemal@sorbonne-universite.fr
o

Institut Universitaire de France, 75005, Paris, France

† Qubit Pharmaceuticals and Sorbonne Université have submitted
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been launched to obtain antivirals able to reduce the impact of
COVID-19 on ill patients. Despite these eﬀorts, few potential
treatments are presently available with the exception of Paxlovid,
a nirmatrelvir/ritonavir combo proposed by Pzer.7 Due to the
persistence of the pandemic, it remains essential to propose new
antiviral drugs. A possible strategy consists in designing small
molecules to interact with one of the main proteins of the SARSCoV-2 virus, thus blocking its activity. Among the potential
targets, the main protease protein, denoted as Mpro or 3CLpro, is
a primary choice8 as it has no human homolog and it is well
conserved among coronaviruses,9 especially in terms of the
structure of its active site, catalytic dyad, and dimer interface.
Furthermore, Mpro is required to release viral proteins for particle
assembly, and is thus essential to the virus replication cycle.
Developing a new drug targeting the viral Mpro is challenging
as it requires extensive resources and the success rate is notoriously low.10 Relying on in silico driven rational design could
accelerate the process. In fact, it diminishes the cost by
reducing the need for synthetic iterations while also providing
an interpretation of the interactions occurring between the
target protein and potential inhibitors.
It is important to note that theoretical modeling of Mpro is
challenging as the protein exhibits high structural exibility11–13
leading to high conformational complexity. Mpro is also
involved in a variety of complex protein–ligand–solvent interaction networks.12,13 These challenges can be tackled using
a high-resolution modeling approach12,13 going beyond rigid
docking procedures (see ref. 14 for a detailed discussion of the
diﬃculties of docking approaches in predicting the native
binding modes of small molecules within Mpro).
Many studies have been devoted to the design of new Mpro
inhibitors3,5,15–25 through joint computational and experimental
approaches. In particular, a recent study by the Jorgensen group
highlighted the usefulness of relative binding free energy
(RBFE) computations as part of the drug design process.26
In this paper, we present a computationally driven discovery
and binding mode rationalization of new SARS-CoV-2 Mpro
inhibitors. In doing so, we build on our previous high-resolution
Mpro molecular dynamics studies.12,13 Here, we explore more
deeply some specic subpockets of the substrate binding site of
the protease using absolute binding free energy (ABFE) calculations and adaptive sampling grounded on extensive molecular
dynamics simulations with high-resolution polarizable force
elds (PFFs). Using the GPU-accelerated module27 (GPU ¼
Graphics Processing Unit) of the Tinker-HP molecular dynamics
package28 coupled to the AMOEBA PFF,29–32 it has been shown that
simulations can reach the required level of accuracy and ms
timescales needed to explore the structural rearrangement and
interactions prole of this exible protein.12,13 More precisely, the
modeling of Mpro necessitates the ability to evaluate at high
resolution various types of key interactions including hydrogen
bonds, salt bridges, p–p stacking, and specic solvation eﬀects.
Long timescales are required to achieve suﬃcient sampling. This
is now possible by using the large number of graphics processing
units (GPUs) that are presently available on supercomputers and
high-performance cloud computing platforms. In this study, we
combine our computationally driven strategy, using absolute

© 2022 The Author(s). Published by the Royal Society of Chemistry
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binding free energy computations33–37 and unsupervised adaptive
sampling,12,13 with machine learning-assisted property predictions, while conducting extensive characterization experiments
including nuclear magnetic resonance (NMR), mass spectrometry
(MS), and FRET-based assays to evaluate the activity of the newly
designed compounds.
In the following, we introduce our design strategy, which led
to non-covalent and covalent inhibitors of Mpro (ESI-Fig. 1‡).
Then, we describe how an interplay between experiments and
molecular simulations allowed the discovery of a nal
compound (QUB-00006-Int-07) with a high aﬃnity to the
protease (IC50 ¼ 830  50 nM).

2.

Computational details

2.1. Systems preparation
The protease dimer structure (PDB code: 7L11) was used for all
the MD simulations and it was prepared at physiological pH (pH
¼ 7). This structure has a higher resolution (1.80 Å) than the PDB
structure (PDB code: 6LU7) used in our previous work12 (resolution of 2.16 Å). Both structures are of the holo state in complex
with covalent inhibitors, and the rotamers of the key residues at
the catalytic site (Cys145, His41, His162, His163, and His172) are
virtually identical. The protonation states of His residues were
assigned based on previous work,38 where His41 and His80 are
protonated at the delta carbon atom and all other His residues
are epsilon-protonated, which is favorable for substrate
binding.38 This is diﬀerent from our previous work where His64
and His80 are protonated at the delta carbon atom and all other
histidines are epsilon-protonated.12 All water molecules were
retained except for those that might collide with the ligands.
2.2. Simulation protocols
All-atom simulations were performed using Qubit Pharmaceuticals' Atlas platform which enables the use of any type of HighPerformance Computing (HPC) system including cloud supercomputing infrastructures. Among its possibilities, Atlas has
the ability to eﬃciently handle polarizable force eld molecular
dynamics simulations using a custom version of the multi-GPU
module27 of the Tinker-HP molecular dynamics package,28,39 to
perform docking runs using either Autodock-Vina40 or Autodock-GPU,41 and to enable machine learning predictions of
molecular properties.
2.2.1. Molecular dynamics simulations. All Tinker-HP MD
simulations (for a total of several ms) were performed in mixed
precision to benet from a strong acceleration of simulations
using GPUs.27 The AMOEBA polarizable force eld29–32 was used
to describe the full systems including the protein, ions and
water. Several utilities (TinkerTools) from Tinker 8 (ref. 42) were
used. Periodic boundary conditions were applied within the
framework of smooth particle mesh Ewald summation43,44 with
a grid of dimensions 120  120  120 using a cubic box with
side lengths of 97 Å. The Ewald cutoﬀ was set to 7 Å, and the van
der Waals cutoﬀ was 12 Å. Langevin molecular dynamics
simulations were performed using the recently introduced
BAOAB-RESPA1 integrator (10 fs outer timestep),45
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a preconditioned conjugate gradient polarization solver (with
a 105 convergence threshold) to solve polarization at each time
step,46 hydrogen-mass repartitioning (HMR) and random initial
velocities. Absolute binding free energy simulations following
a protocol described in the next section were performed as well
as adaptive sampling runs that are also described further in the
text. Absolute binding free energy computations were both
performed on the HPE Jean Zay Supercomputer (IDRIS, GENCI,
France) and on Amazon Web Services (AWS). All adaptive
sampling computations were performed using AWS. Simulations on AWS used both p3.2x (NVIDIA V100 GPU cards) and
p4d.24xlarge (NVIDIA A100 GPU cards) instances whereas
computations on the Jean Zay supercomputer were powered by
V100 cards.
2.2.2. Molecular docking protocol. The protonation states
of the ligands were calculated at a neutral pH and the hydrogen
atoms were added using Chimera. Next, we docked the ligands
QUB-00006-Int-01(R) and QUB-00006-Int-01(S) into the Mpro
dimer structure using Autodock Vina 1.1.2.40 AutoDock Vina
requires the pdbqt format for the input les of the receptor and
the ligand. Therefore, using the scripts ‘prepare_receptor4.py’ (v
1.13) and ‘prepare_ligand4.py’ (v 1.10) provided by Autodock
Tools,47 we generated pdbqt les corresponding to the receptor
and the ligands, respectively. We set the exhaustiveness search
to 100 and the num_mode option to 50.
Since molecular docking could suggest reasonable potential
binding modes, but does not always rank the most likely binding
mode as the best docked pose,14,48 we visually inspected the
generated docked poses and chose an ensemble of binding poses
with diﬀerent binding orientations that we used to run MD and
ABFE calculations in order to explore the binding mode of QUB00006-Int-01, as described in the Results and discussion section.
2.2.3. Equilibration. A detailed description of the equilibration protocol used for MD simulations can be found in the ESI.‡
2.2.4. High-resolution adaptive sampling simulations.
Starting from several binding poses as described above we ran
adaptive sampling simulations using the AMOEBA force
eld29–32 in order to explore their stability and more generally to
explore the conformational space of the ligands in the pocket of
the Mpro. Because of the exibility of the pocket and the role it
may play in the exploration of the potential binding modes of
the ligand, we chose to keep the whole system (ligand + protein)
exible during this sampling phase. The restart strategy (similar
to the one introduced in ref. 12) was the following: rst, all the
previously generated conformations of the protein were loaded
and aligned with MDTraj,49 then PCAs of the conformations of
the ligand were computed using Scikitlearn50 and these frames
were projected on the rst four PCAs. Finally, the same scheme
as the one described in ref. 12 was used to generate new starting
points, favoring points that were less explored during the
previous phases. In practice, a rst set of 5 simulations of 10
nanoseconds were performed using diﬀerent random seeds,
and then 4 iterations of 10 times 10 nanoseconds were generated using the adaptive sampling protocol described above, for
a total of 450 nanoseconds.
2.2.5. Absolute binding free energy calculations. In order to
benet from the high-accuracy evaluation of free energies using
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the AMOEBA force eld,33–37 we used the same clustering algorithms as described above to analyze the adaptive molecular
dynamics simulations. The largest clusters were used for absolute
free energy calculations. The double-decoupling protocol and the
Bennett acceptance ratio (BAR)51 method were used to calculate
the standard binding free energy for each binding pose.33,37 There
were 27 or 26 thermodynamic states for the decoupling in the
complex phase or the aqueous phase. A distance restraint
between two groups of atoms in the ligand and in the protein
binding pocket was applied when decoupling the ligand in the
complex to accelerate the convergence when the ligand is fully
decoupled, and the restraint was removed at an additional step at
the full interaction state. A harmonic restraint with a force
constant of 15.0 kcal mol1 Å2 and radius of 2.0 Å was used. An
analytical correction was added to the binding free energy to
account for the standard state at 1.0 mol L1 in the fully decoupled state. 10 ns simulations were performed for each thermodynamic state for the simulations of Mpro in complex with x0195,
QUB-00006(S), QUB-00006(R), and QUB-00006-Int-07. For the
simulations of Mpro in complex with QUB-00006-Int-01(R) and
QUB-00006-Int-01(S), we ran each thermodynamic state for 20 ns.
We used the BAOAB-RESPA1 integrator with a 10 fs time step and
we calculated the electrostatic interactions using Ewald summation with a real space cutoﬀ of 7 Å. van der Waals interactions
were calculated using a cutoﬀ of 12 Å with long-range correction.
2.3. Quantitative structure–property relationship (QSPR)
modeling: predicting solubility using machine learning
Qubit Pharmaceuticals' Atlas internal machine learning-based
QSPR module was used to predict the water solubility (log S, S
measured in mol L1) and octanol/water partition coeﬃcient
(log P). To build a water solubility QSPR predictor, the AqSolDB
dataset52 was used as a training set. To predict octanol/water
partition coeﬃcients (log P), the dataset from EPA's OPERA53 was
used as a training set.
Selected datasets were preprocessed and standardized to
some extent by authors of the corresponding publications.
However, the need for additional processing was identied
when doing exploratory data analysis. We discarded
compounds with less than two carbon atoms and kept molecules with molecular weight between 50 and 750 daltons.
Additional rules of fragment standardization developed at
Qubit Pharmaceuticals were applied.
2.3.1. Similarity analysis. Tanimoto similarity54 to the
x0195 compound was calculated for each molecule using the
MAACS ngerprint from the RDKit Open-Source Cheminformatics Soware (https://www.rdkit.org). The Morgan
circular ngerprint55 with radius ¼ 2 and nBits ¼ 2048 from
RDKit was also tested and the results (not shown) exhibit
a similar ranking of the compounds.

3.

Experimental protocol

3.1. Recombinant expression of SARS-CoV-2 Mpro in E. coli
The plasmid pGEX-6P-1 encoding SARS-CoV-2 Mpro56 was
a generous gi from Prof. Rolf Hilgenfeld, University of Lübeck,
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Lübeck, Germany. Protein expression and purication were
adapted from Zhang et al.56 The expression plasmid was transformed into E. coli strain BL21 (DE3) and then pre-cultured in
YT medium at 37  C (100 mg mL1 ampicillin) overnight. The
pre-culture was used to inoculate fresh YT medium supplied
with an antibiotic and the cells were grown at 37  C to an OD600
of 0.6–0.8 before induction of overexpression with 0.5 mM isopropyl-D-thiogalactoside (IPTG). Aer 5 h at 37  C, cells were
harvested by centrifugation (5000g, 4  C, 15 min) and frozen.
The pellets were resuspended in buﬀer A (20 mM Tris, 150 mM
NaCl, pH 7.8) supplemented with lysozyme, DNase I and PMSF
for the lysis. The lysate was claried by centrifugation at 12 000g
at 4  C for 1 h and loaded onto a HisTrap HP column (GE
Healthcare) equilibrated with 98% buﬀer A/2% buﬀer B (20 mM
Tris, 150 mM NaCl, 500 mM imidazole, pH 7.8). The column
was washed with 95% buﬀer A/5% buﬀer B and then His-tagged
Mpro was eluted with a linear gradient of imidazole ranging
from 25 mM to 500 mM. Pooled fractions containing the target
protein were subjected to buﬀer exchange with buﬀer A using
a HiPrep 26/10 desalting column (GE Healthcare). Next, PreScission protease was added to remove the C-terminal His tag (20
mg of PreScission protease per mg of target protein) at 12  C
overnight. Protein solution was loaded onto a HisTrap HP
column connected to a GSTrap FF column (GE Healthcare)
equilibrated in buﬀer A to remove the GST-tagged PreScission
protease, the His-tag, and the uncleaved protein. Mpro was
nally puried with a Superdex 75 prep-grade 16/60 (GE
Healthcare) SEC column equilibrated with buﬀer C (20 mM
Tris, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, pH 7.8). Fractions
containing the target protein at high purity were pooled,
concentrated at 25 mg mL1 and ash-frozen in liquid nitrogen
for storage in small aliquots at 80  C.
3.2. Protein characterization and enzymatic activity
The molecular mass of the recombinant SARS-CoV-2 Mpro was
determined by direct infusion electrospray ionization mass
spectrometry (ESI-MS) on a Xevo G2-XS QTOF mass spectrometer (Waters). Samples were diluted in 50% acetonitrile with
0.1% formic acid to achieve a nal 1 mM concentration of
protein. The detected species displayed a mass of 33 796.64 Da,
which matches very closely the value of 33 796.81 Da calculated
from the theoretical full-length protein sequence (residues 1–
306). To characterize the enzymatic activity of our recombinant
Mpro, we adopted a FRET-based assay using the uorogenic
substrate 5-FAM-AVLQ0 SGFRK(DABCYL)K (ProteoGenix) harbouring the cleavage site of SARS-CoV-2 Mpro (0 indicates the
cleavage site). The uorescence of the intact peptide is very low
since the uorophore 5-FAM and the quencher Dabcyl are in
close proximity. When the substrate is cleaved by the protease,
the uorophore and the quencher are separated, increasing the
uorescence signal. Freshly unfrozen recombinant SARS-CoV-2
Mpro was used in our assays. The assay was performed by mixing
0.05 mM Mpro with diﬀerent concentrations of substrate (1–128
mM) in the reaction buﬀer (20 mM Tris–HCl, 100 mM NaCl, 1
mM EDTA and 1 mM DTT, pH 7.3) in the nal volume of 100 mL.
Fluorescence intensity (Ex ¼ 485 nm/Em ¼ 535 nm) was

© 2022 The Author(s). Published by the Royal Society of Chemistry
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monitored at 37  C with a Victor3 microplate reader (PerkinElmer) for 50 min. A calibration curve was created by
measuring multiple concentrations (from 0.001 to 5 mM) of free
uorescein in a nal volume of 100 mL reaction buﬀer. Initial
velocities were determined from the linear section of the curve,
and the corresponding relative uorescence units per unit of
time (DRFU/s) were converted to the amount of the cleaved
substrate per unit of time (mM s1) by tting to the calibration
curve of free uorescein. Inner-lter eﬀect corrections were
applied for the kinetic measurements according to ref. 57. The
catalytic eﬃciency kcat/km resulted in 4819  399 s1 M1, in
line with literature data.56,58
3.3. Nuclear magnetic resonance
All the NMR screening experiments were performed with
a Bruker Neo 600 MHz spectrometer, equipped with a nitrogen
cooled 5 mm Prodigy CryoProbe at 298 K. The ligand binding
was monitored by WaterLOGSY (wLogsy)59 and Saturation
Transfer Diﬀerence (STD)60 experiments in the presence and in
the absence of the protein. Samples contained 10 mM Mpro and
100 mM to 2 mM ligand dissolved in 150 mM NaCl, 20 mM
phosphate, 5% D2O, and 4% DMSO-d6 (pH ¼ 7.3). WaterLOGSY
experiments were performed with a 180 inversion pulse
applied to the water signal at 4.7 ppm using a Gaussian-shaped
selective pulse of 5 ms. Each WaterLOGSY spectrum was
acquired with 320 scans, a mixing time of 1.5 s and a relaxation
delay of 4.5 s. STD experiments were performed with 256 scans.
Selective saturation of the protein at 0.4 ppm frequency was
carried out by a 2 s pulse train (60 Gaussian pulses of 50 ms
separated by 1 ms intervals) included in the relaxation delay and
a 30 ms spin-lock was used to reduce the broad background
protein signal. The estimation of the KD was achieved by a STD
titration according to a previously reported procedure and
tting the curves using OriginPro 2018 (OriginPro version 2018
developed by OriginLab Corporation, Northampton, MA, USA).
The water suppression was achieved by the excitation sculpting
pulse scheme.
3.4. Screening of potential Mpro inhibitors and hits
validation
A FRET-based assay employed to test the enzymatic activity of
the recombinant SARS-CoV-2 Mpro was used to evaluate the
ability of the compounds to inhibit its activity in vitro. In fact,
inhibition of Mpro by the tested compounds results in
a decrease of the uorescence signal compared to the Mpro
activity in the absence of an inhibitor. A preliminary screening
was rst performed at a single compound concentration to
rapidly identify the ability of the compounds to inhibit Mpro
activity and to rank them according to their inhibitory activity.
The protein was diluted in the reaction buﬀer (20 mM Tris–
HCl, 100 mM NaCl, 1 mM EDTA and 1 mM DTT, pH 7.3) and
pipetted into a 96-well plate to a nal protein concentration of
0.02 mM in a nal volume of 100 mL. Each compound at the
nal concentration of 100 mM was incubated with Mpro for 20
minutes at room temperature. Aer incubation, the peptide
substrate (5 mM nal) was added to initiate the reaction which
Chem. Sci., 2022, 13, 3674–3687 | 3677
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was monitored for 50 min at 37  C. The nal DMSO amount
was 3.75%. Two controls were prepared for each experiment:
the peptide substrate in the absence of Mpro (0% Mpro activity,
hence minimal uorescence intensity detected) and the reaction mixture in the absence of the compounds (100% Mpro
activity, therefore maximal uorescence intensity detected).
Following the preliminary screening, the most active
compounds (hits) were tested at increasing concentrations
(0.25, 0.5, 1, 5, 25, 50, 100, and 150 mM) to determine the dose–
response curves and calculate IC50 values tted using GraphPad Prism 5 soware. Each experiment was performed in
triplicate and the results were used to calculate an average and
a standard deviation.

Edge Article
3.5. Binding studies by mass spectrometry
Samples were prepared by mixing appropriate volumes of Mpro
(10 mM nal) with each compound in the reaction buﬀer (20 mM
Tris–HCl, 100 mM NaCl, 1 mM EDTA and 1 mM DTT, pH 7.3).
The nal mixtures had a 1 : 1 or 10 : 1 compound : protein
molar ratio. Samples were incubated at room temperature for 20
min before analysis. Control experiments were performed on 10
mM solutions of Mpro in the absence of the compounds. Mass
spectrometric analyses were carried out in positive ion mode by
ESI-MS under denaturing conditions, i.e. water/acetonitrile
50 : 50 with 0.1% formic acid on a Q-Tof Xevo G2S (Waters,
Manchester, UK). Data were processed using MassLynx V4.1
soware.

Reﬁnement of the co-crystal structure of x0195 and Mpro using MD simulations. (A) An unusual conformation of x0195 (in purple) located
in the binding pocket formed by His41, Met49, Glu166, Gln189, and Pro168 and their surroundings (PDB code: 5R81), and (B) the relaxed structure
of x0195 (in purple), obtained after the equilibration step, interacting with the amino acid residues of the substrate binding site. Mpro is shown in
light grey. (C) Torsion angle distribution for the sulfonamide group during 20 ns of MD simulations (in blue) performed on the Mpro dimer in
complex with x0195; the torsion angle of the sulfonamide group in the co-crystal structure is shown in pink. (D) Torsion energy scan calculated
by AMOEBA (in blue) and QM (in orange); the torsion angle of the sulfonamide group in the co-crystal structure is shown in pink. QM level ¼
uB97x-D/6-31g*.65–67
Fig. 1
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3.6. Synthesis
The detailed synthetic protocol used to prepare all molecules
can be found in the ESI.‡
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4. Results and discussion
Several diverse fragments binding the viral Mpro have been
identied by high-throughput crystallographic screening of this
protease. Among the screened fragments, x0195 (PDB ID: 5R81
(ref. 61) – Fig. 1A) shows one of the highest binding aﬃnities62
and therefore provides a reasonable starting point for fragmentbased design of novel Mpro inhibitors.
The crystal structure shows that x0195 is located within the
Mpro substrate binding pocket, at the interface of the two subpockets S2 and S4 as described by Cannalire et al.63 S4 is
a solvent exposed subpocket that is partially composed of
a exible loop delimited by Gln189 and Gln192, while S2 is
dened by the side chain residues of Phe140, Asn142, His163,
Glu166, and His172, and the backbone atoms of Phe140 and
Leu141.
In the co-crystal structure corresponding to Mpro in complex
with x0195 (see Fig. 1A), the aromatic portion of the molecule is
located between the side chains of Gln189 and Met 165, while
the unsaturated region of the tetrahydroquinoline scaﬀold
establishes a hydrophobic interaction with the side chains of
His41 and Met49. The N-methyl group attached to the tetrahydroquinoline core is solvent exposed, while the sulfonamide
moiety is in contact with Pro168 and Glu166. In particular, the
aromatic ring of the small molecule is bisecting the SO2 unit
and the polar sulfonamide nitrogen (–NH2) is reaching the
boundaries of the hydrophobic part of the binding pocket
composed of the alkyl chain of Pro168.
Aer comparing the available X-ray structural information
with previously conducted studies on small molecule conformational preferences derived from crystal structure data,64 we
noticed that x0195 was modeled in a high energy conformation
and that an unusual high-energy (i.e. repulsive) contact occurs
between the sulfonamide oxygen and the carbonyl oxygen of the
Glu166 backbone. Additionally, the tetrahydroquinoline scaffold was not fully exploring S2 subpocket boundaries. As reported by Cannalire et al.63 and Zhang et al.,8 the volume of the
S2 subpocket in SARS-CoV Mpro is very similar to that of the
MERS-CoV homologue. However, the volume of S2 in SARS-CoV
Mpro (252 Å3) is signicantly larger than in other CoV homologues of the a-genus, such as the HCoV-NL63 Mpro (45 Å3).8,63

Fig. 2

Chemical Science
Therefore, exploiting this knowledge might be key to designing
specic inhibitors of CoV Mpro.
In order to rene the available X-ray structural model and to
gather more structural insights (e.g. protein exibility and
binding pocket rearrangements12,13) to guide the design of
better binders of the subpocket S2, we ran all-atom molecular
dynamics simulations using the AMOEBA polarizable force
eld29–32 on Mpro (PDB code: 7L11) in complex with x0195 (PDB
code: 5R81).
Our simulations show that the unusual high-energy contacts
between the sulfonamide oxygen and the carbonyl oxygen of the
Glu166 backbone no longer occurred. Also, regarding the electronic structure, we noticed that the p orbitals of the aromatic
carbon C1 bisect (e.g. are parallel to) the SO2 angle, compared
with a 90 value for the same angle as reported in the crystal
structure (see Fig. 1). Moreover, the NH2 of the sulfonamide
group is engaged in favorable polar interactions with the
Gln189 side chain and the solvent.
Then, we performed absolute binding free energy calculations on the rened protein–ligand structure. Our results show
that x0195 binds to the protein with a binding free energy of
2.83 kcal mol1 at 283 K, which is comparable to the experimental binding energy (3.59  0.1 kcal mol1, see Table 1).
We obtained the experimental binding free energy by converting the experimental Kd (1.7 mM  0.2) provided in the
literature62 using the Gibbs free energy equation and the
experimental temperature used in the binding assays (283 K).
The agreement of the computed free energy prediction with the
experimental results is reasonable. Further analysis of MD
simulations suggests that the tetrahydroquinoline scaﬀold of
x0195 is sub-optimally occupying the binding pocket.
We put in place design strategies to modify the chemical
moieties of x0195 and potentially increase its binding aﬃnity.
Here, we introduce the design of a new molecule, namely QUB00006 (Fig. 2), where we added two uorines and a methyl group
on the tetrahydroquinoline core of x0195. Also, we substituted
the sulfonamide group on the aromatic ring of the molecule by
a methanethiol. Fluorination at position 3 of the tetrahydroquinoline core could increase ligand occupancy with no
disruption of the water network surrounding the binding
pocket,12,13 while methylation at position 4 seemed an interesting modication to increase the potential interactions of the
ligand with binding pocket residues. QUB-00006 was generated
based on the structure and position of x0195 in the co-crystal
(5R81), and then placed in the receptor structure (Mpro dimer

2D structures of (A) x0195, (B) QUB-00006-Int-01, (C) QUB-00006-Int-07, and (D) QUB-00006. The asterisk represents a chiral center.
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Experimental and computed binding free energies (kcal
mol1) for the non-covalent compounds. N.A. ¼ not available (see text
for details)
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Table 1

Compound

Computed DG

Experimental DG

QUB-00 006(R)
QUB-00 006(S)
QUB-00 006-Int-01(R)
QUB-00 006-Int-01(S)
x0195
QUB-00 006-Int-07

2.73 
2.72 
4.30 
4.45 
2.83 
5.37 

N.A.

0.34
0.22
0.35
0.29
0.66
0.23

3.71  0.2
3.59  0.1
Covalent binder

with the PDB code: 71LL); next, the Mpro–QUB-00006 complex
was equilibrated using MD simulations (see ESI Section 1‡ for
the detailed protocol), followed by free energy calculations. To
explore the potential of our computational platform in
designing new binders with no or few experimental data such as
ligand–Mpro co-crystal structures, we leveraged all-atom molecular dynamics simulations on QUB-00006 complexed with Mpro.
The aim of this approach is to gather insights on the binding
conformation of the newly in silico designed ligand, assess
pocket tness, and evaluate its binding aﬃnity using ABFE
calculations.
The initial molecular conformation is mostly anchored at the
binding pocket, with the a,a-diuoro-methyl group attached to
the tetrahydroquinoline core fully occupying the buried part of
the S2 subpocket, which is composed of the side chains of
Met49 and His41, while the sulfonamide moiety extends to S4
(Leu167 and Pro168). We note that methylation at position 4 of
the tetrahydroquinoline core introduces a chiral center,
however no signicant diﬀerences in terms of pocket occupancy
between the R and S enantiomers were observed.
The computed absolute binding free energies for QUB00006(R) and QUB-00006(S) are 2.73  0.34 kcal mol1 and

2.72  0.22 kcal mol1, respectively (Table 1). These results
suggest that the designed uorinated fragment is a binder at
the Mpro S2 subpocket and could represent a starting point for
structure-based design of novel Mpro inhibitors.
The identied binding mode is dened by several favorable
intermolecular interactions occurring between the newly
designed ligand and the Mpro binding pocket: (i) the sulfur
group of QUB-00006(R) interacts with the oxygen of the carbonyl
belonging to the backbone of Glu166 with a distance of 3.3 Å,
(ii) the a,a-diuoro moiety points towards His41, and (iii) the
sulfur of Met49 establishes a favorable interaction with one of
the two uorines of the substrate (distance 3.3 Å). In fact, the
sulfur–oxygen contact observed in our simulations is in agreement with the ndings of a study conducted by Iwaoka et al.,68
where they found that a total of 1200 and 626 fragments from
the Cambridge Structural Database (CSD) and Protein Data
Bank (PDB), respectively, have close intermolecular S–O
contacts (with a distance of 3.52 Å or less). Another study
analyzing the protein structures deposited in the Protein Data
Bank reports 1133 interactions between His and halogen atoms
found in 3833 PDB entries with one or more halogenated
ligands co-crystallized with a protein.69 Moreover, the strong S–
F interaction identied during the simulations is in good
agreement with experimentally observed distances for uorine–
sulfur contacts in crystal structures (2.8–3.4 Å).70 It is worth
noting that such interactions involving sulfur and halogen
atoms are usually better captured with polarizable models than
with their classical counterparts.71–73
QUB-00006 was then synthesized following the path in Fig. 4
in order to validate in vitro the simulation outcomes.
The ligand orientation in the MD simulations and the
computed hydration ratio of the diﬀerent atoms of QUB-00006
during ABFE simulations suggest that proton C is solvent
exposed, while the protons of the methyl thioether group (group

Fig. 3 Computational and experimental characterization of QUB-00006 binding within the Mpro binding pocket. (A) QUB-00006(R) (in light
green) and QUB-00006(S) (in cyan) binding in a similar fashion at the interface of subpockets S2 and S4; the binding poses shown here were
clustered and extracted from the trajectories of the binding free energy calculations performed on QUB-00006(R) and QUB-00006(S). (B) The
analysis of our binding free energy trajectories showing that protons in groups A, B, E, and D have a low hydration ratio (less than 0.5), while the
proton of group C has a high hydration ratio of 0.8. Hydration ratios calculated for the diﬀerent proton groups of QUB-00006(R) correlate with
those calculated for QUB-00006(S). (C) The WaterLOGSY spectra of QUB-00006 in the presence and absence of the Mpro. The assignment
scheme is reported along with the 2D structure of the ligand. The strong negative intensity of the signals of the hydrogens of groups A, D, and E
suggests that they are orientated towards the protein, while the hydrogen atom in C is solvent exposed. These experimental ﬁndings conﬁrm the
hydration ratio calculated during our binding free energy simulations and described in panel B.
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E) and the methyl group at position 4 of the tetrahydroquinoline
core (group D) are buried (Fig. 3B).
Those ndings strongly correlate with the NMR characterization of QUB-00006 obtained via WaterLOGSY experiments. In
fact, WaterLOGSY epitope mapping conrms that QUB-00006
binds to the protein binding pocket. We leveraged the experimental approach to better identify the region of the ligand in
contact with the protein. In Fig. 3C, the proton signals arising
from the two methyl groups (D and E) in the presence of Mpro
show a change in the sign suggesting that these protons are in
close contact with the protein. Similarly, the aromatic protons A
and B undergo a sign inversion. In contrast, the aromatic
proton C is not signicantly perturbed, which suggests that this
position is solvent exposed. The binding mode suggested by
NMR is in agreement with the MD-derived hydration ratios
conrming the predictive power of our MD-based approach to
characterize the binding mode of novel ligands at the experimental level of accuracy (Fig. 3B and C).
Although we were able to gather structural information
about the binding mode of QUB-00006 using a WaterLOGSY
assay, we could not measure its experimental binding aﬃnity
via STD NMR due to solubility challenges.
Several synthetic steps were performed in order to obtain
QUB-00006, as detailed in Fig. 4. Through this synthetic
scheme, we obtained diﬀerent intermediates characterized by
a better solubility prole (Table 2). Interestingly, the hydroxyquinolinone QUB-00006-Int-01 displayed the best solubility
prole of all the synthetic intermediates, making it a strong
candidate for in vitro evaluation.
Before conducting NMR STD experiments to determine the
dissociation constant (Kd) of the more polar QUB-00006-Int-01

Chemical Science
Table 2 Prediction of the properties of compounds using our
machine learning workﬂow. MW represents the molecular weight of
the compounds in daltons, log S is the predicted solubility of the
diﬀerent compounds, log P represents the diﬀerential solubility, and
the Tanimoto coeﬃcient reﬂects the similarity of the selected
compounds relative to x0195

QUB-00 006
QUB-00 006-Int-07
QUB-00 006-Int-01
x0195

MW (Da)

log S

log P

Tanimoto (MACCS)

229.07
243.02
245.03
226.08

3.99
3.73
2.73
1.94

3.56
1.96
1.66
0.56

0.391
0.371
0.338
1

compound, we decided to predict its binding conformation at
the binding pocket and compute the respective absolute
binding free energy. Modication of the molecular scaﬀolds,
especially in fragment-like molecules, might aﬀect the binding
mode74 compared to a reference structure (e.g. x0195 as per PDB
ID:5R81).
We used a combination of docking, MD and ABFE calculations to explore the putative binding mode of QUB-00006-Int-01.
Those calculations identied two dominant binding modes for
QUB-00006-Int-01(R) and QUB-00006-Int-01(S) (Fig. 5A) with
computed binding free energies of 4.4 and 4.3 kcal mol1,
respectively. Then, we estimated the binding aﬃnity of QUB00006-Int-01 towards Mpro by a STD NMR titration and we found
a dissociation constant in the low millimolar range, with an
estimated Kd of 1.9  0.6 mM (3.71  0.2 kcal mol1), which
agrees reasonably well with our binding free energy calculations
(Table 1). As shown in Fig. 5A, both enantiomers bind to the S2
and S4 subpockets with the thioether group being fully buried

Fig. 4 Synthesis path of 3,3-diﬂuoro-4-methyl-7-(methylsulfanyl)-1,2,3,4-tetrahydroquinoline named QUB-00006.

© 2022 The Author(s). Published by the Royal Society of Chemistry
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Fig. 5 Computational and experimental characterization of QUB-00006-Int-01 in the Mpro binding pocket. (A) The dominant binding modes of
QUB-00006-Int-01(R) (in pink) and QUB-00006-Int-01(S) (in magenta), identiﬁed during ABFE simulations. They have computed binding free
energies of 4.4 and 4.3 kcal mol1, respectively; also, they bind to the S2 and S4 subpockets in a similar fashion with the thioether group being
fully buried in S2. On the other hand, starting with a QUB-00006 like binding mode, we ran an additional absolute binding free energy calculation
on Mpro in complex with QUB-00006-Int-01(R) and obtained a second binding mode for QUB-00006-Int-01(R) (in green) with a binding free
energy of 0.9 kcal mol1. (B) STD titration proﬁle of QUB-00006-Int-01. The ligand concentration ranges from 100 mM to 2 mM against 10 mM
of Mpro. (C) The WaterLOGSY spectra of QUB-00006-Int-01 with Mpro (in blue) and without Mpro (in red). The assignment of the signals is reported on the 2D structure of the fragment. The methyl and the aromatic signals of the two protons adjacent to the hydroxyl group undergo
a signiﬁcant change, which suggests that these groups are in close contact with the protein's cavity. In contrast, the aromatic proton adjacent to
the lactamic nitrogen undergoes a reduction of its intensity, suggesting that this proton is partially exposed to the solvent. These STD results
conﬁrm our computational characterization of the binding mode of QUB-00006-Int-01 (panel A).

in subpocket S2, which correlates with WaterLOGSY experiments (Fig. 5C). Additionally, QUB-00006-Int-01(R) and QUB00006-Int-01(S) ll up a binding pocket space that is diﬀerent
from the one occupied by QUB-00006. On the other hand,
starting with a QUB-00006-like binding mode, we ran an additional absolute binding free energy calculation on an Mpro–

3682 | Chem. Sci., 2022, 13, 3674–3687

QUB-00006-Int-01(R) complex and obtained a binding free
energy of 0.9 kcal mol1. These results suggest that QUB00006-Int-01 and QUB-00006 might have diﬀerent dominant
binding conformations (see Fig. 3A and 5A).
Since a fragment-like molecule could have multiple binding
modes and the ligand conformation is unlikely to be fully
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Table 3 Population of the clusters generated by adaptive sampling
performed on Mpro in complex with QUB-00 006-Int-01(R) and (S).
DDG (kcal mol1) is the relative free energy at 298 K. The relative
binding free energies reported for QUB-00 006-Int-01(R) and (S) are
calculated using the respective cluster 1 as a reference ligand
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QUB-00 006-Int-01(R)

QUB-00 006-Int-01(S)

Cluster

Fraction

DDG

Cluster

Fraction

DDG

1
2
3
4
5
6
7
8
9
10

0.101
0.083
0.067
0.053
0.042
0.035
0.034
0.033
0.032
0.032

0
0.05
0.11
0.17
0.23
0.27
0.28
0.29
0.30
0.30

1
2
3
4
5
6
7
8
9
10

0.103
0.093
0.088
0.065
0.059
0.054
0.049
0.039
0.033
0.031

0
0.03
0.04
0.12
0.14
0.17
0.19
0.25
0.29
0.31

Fig. 6 Conformations of QUB-00006-Int-01 sampled during 20 ns of
ABFE calculations and 450 ns of adaptive sampling simulations. The
conformation was plotted as a function of two distances: (i) the
distance between C2 (carbon of QUB-00006-Int-01 connected to the
hydroxyl group) and the sulfur of Cys145, and (ii) the distance between
the methyl thioether group in QUB-00006-Int-01 and the beta carbon
of Gln189. “0” indicates the starting structure, “1” indicates the largest
cluster, and “i” indicates the ith largest cluster. The frames were taken
at 10 ps time intervals.

sampled during 20 ns of binding free energy simulations, we
used unsupervised adaptive sampling (AS) to further explore the
conformational space of QUB-00006-Int-01. AS can be used here
as an interpretative tool able to gather structural insights on the
various potential Mpro–ligand interactions (see the ESI‡ for
details). The AS trajectories were clustered using averagelinkage hierarchical clustering algorithms and the top ten
largest clusters were chosen for analysis. These clusters have
comparable populations (the smallest clusters have 3–4 times
smaller populations or 0.3 kcal mol1 higher free energy than
the largest clusters, see Table 3), indicating the coexistence of
multiple binding modes.
More precisely, starting from these clusters, absolute
binding free energies would yield results within 0.3 kcal mol1
of what was previously obtained. The simulations of QUB00006-Int-01(R) and QUB-00006-Int-01(S) converged to similar

© 2022 The Author(s). Published by the Royal Society of Chemistry

ensembles containing several possible binding modes. Clusters
3, 5, and 6 of QUB-00006-Int-01(R) and cluster 4 of QUB-00006Int-01(S) (ESI-Fig. 2‡) correspond to the respective dominant
binding modes predicted by ABFE simulations (Fig. 5A). For
both enantiomers, the most conserved interactions are the
hydrophobic contacts between C9 (methyl thioether) and
Gln189, and between C5 (proton B) and His41, Arg188, and
Gln189.
Overall, our computational ndings on QUB-00006-Int-01
conrm that the structural approach we introduce in this work
using a sequence of MD-based techniques (classical MD simulations, adaptive sampling, and absolute binding free energy
calculations) is able to capture potential binding orientations of
fragment-like compounds in the binding pocket of a protein,
and to accurately predict their binding free energies.
Then, we analyzed the clustered QUB-00006-Int-01 binding
conformations from the adaptive sampling simulations plotted
as a function of the distance between the methyl thioether
group in QUB-00006-Int-01 and the beta carbon of Gln189, and
the distance between C2 (carbon connected to the hydroxyl
group) and the sulfur atom (SG) of the catalytic side chain of the
Cys145 residue (Fig. 6). We noticed that the distance of C2–SG
in the most populated cluster generated by the AS simulations is
around 4 Å. To reinforce our analysis, we leveraged another
unsupervised reduction of dimension technique: TICA (timelagged independent component analysis),75 which aims at
nding the slow collective variables of the data, and applied it to
QUB-00006-Int-01(R). We then used the k-means clustering
method on the data projected on this space and built a Hidden
Markov State Model (HMSM).76 Three clusters emerged, whose
characteristics also show the coexistence of several binding
modes of QUB-00006-Int-01(R), one of which corresponds to
a distance between C2 and SG below 4 Å. Detailed results can be
found in the ESI.‡
Targeting Cys145 with covalent warheads has been used by
several researchers to discover novel potent inhibitors of
Mpro.38,63,77 As a matter of fact, a simple chemical modication to
QUB-00006-Int-01 would lead to QUB-00006-Int-07 bearing an
a,a-diuoro-keto moiety, which is prone to a nucleophilic attack
by the vicinal R-SH of Cys145. In order to enable the latter, QUB00006-Int-07 would need to access the Mpro substrate pocket
and adopt a stable binding conformation prior to the covalent
binding. Thus, we conducted absolute binding free energy
simulations on the Mpro–QUB-00006-Int-07 complex, which
conrmed a favorable binding energy of QUB-00006-Int-07 to
the Mpro substrate pocket (5.37  0.23 kcal mol1). As reported
in Fig. 7, compound QUB-00006-Int-07 is bound to the S2 and S4
subpockets with the thioether group being fully buried in subpocket S2 and the a,a-diuoro-keto moiety facing Cys145. More
precisely, the average distance between SG and the C is 3.65
angstroms (0.33) and the average distance between the SG and
C2 is 3.61 angstroms (0.43) as can be seen in Fig. 7.
Our computational ndings motivated us to test the
compound with a FRET-based proteolytic assay. This assay
should detect potent functional binders to the viral Mpro. Being
a uorogenic assay, compounds with uorescence quenching
properties can suppress the uorescence signal generated by
Chem. Sci., 2022, 13, 3674–3687 | 3683
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Dose–response curves obtained by plotting the percentage of
SARS-CoV-2 Mpro residual activity as a function of increasing
concentrations of QUB-00006-Int-07 (0–150 mM). [Mpro] ¼ 20 nM,
[PS1] ¼ 5 mM, %DMSO ¼ 3.75%. Experiments were performed in triplicate. A counter screening control experiment was performed by
testing increasing concentrations of QUB-00006-Int-07 in the presence of 0.5 mM free ﬂuorescein.
Fig. 8

Fig. 7 The dominant binding mode of QUB-00006-Int-07 during
ABFE simulations. (A) Time evolution of key distances in the simulation.
“SG” stands for the sulfur atom in Cys145, “C” is the amide carbon in
QUB-00006-Int-07, and “C2” is the carbonyl carbon in QUB-00006Int-07. The average distances for SG–C and SG–C2 are 3.61 Å and 3.65
Å, respectively. (B) The dominant binding mode of QUB-00006-Int-07
within the Mpro binding pocket. QUB-00006-Int-07 is shown in pink
and the protein is shown in silver sticks and surfaces. The binding
mode is very stable during the simulation, where the hydroxyl group is
close to Cys145 and forms a hydrogen-bond with the Glu166 backbone, and the diﬂuoro group interacts with the carbonyl group of
Asn142. These binding modes are also comparable to the dominant
binding mode of QUB-00006-Int-01(S) identiﬁed during ABFE
calculations.

the protease activity. To eliminate false positive results, we
conducted a preliminary counter screen and veried that the
tested compound possesses negligible uorescence quenching
eﬀects. Subsequently, to assess the potential inhibitory activity
of the compound against SARS-CoV-2 Mpro, increasing concentrations of QUB-00006-Int-07 (0.25–150 mM) were incubated
with 20 nM Mpro before the addition of 5 mM FRET substrate. As
shown in Fig. 8, QUB-00006-Int-07 inhibited Mpro with 50%
inhibitory concentration (IC50 value of 830  50 nM), thus
resulting in a fairly potent inhibitor of the Mpro enzymatic
activity. The binding of QUB-00006-Int-07 to Mpro was
conrmed by electrospray ionization (ESI) mass spectrometry.
A preliminary determination of the initial protein showed an
experimental mass of 33 796.40 Da, which matches very closely
the expected value of 33 796.64 Da calculated from the sequence

3684 | Chem. Sci., 2022, 13, 3674–3687

(Fig. 9A). The sample obtained aer incubation of QUB-00006Int-07 with Mpro (compound : protein ratio ¼ 10 : 1) was
analyzed by ESI-MS under denaturing conditions, and a representative spectrum is provided in Fig. 9B. In addition to the
signals corresponding to multiple charge states of the initial
protein (red dots), we identied the distribution of signals
corresponding to the Mpro modied by the presence of the
compound (green asterisks) which is therefore covalently linked
to the protein given the non-native conditions of the experiment. The nature of the adduct and the molecular mechanism
of binding are under investigation and will be the subject of
further studies.
Finally, in this work, the introduction of multiple modications (e.g. gem-diuoro, thioether, hydroxyl and methyl groups)
to the tetrahydroquinoline scaﬀold of x0195, and the design and
synthesis of novel molecular scaﬀolds, enabled the exploration
of binding pocket boundaries and provided additional information related to druggability of the S2 subpocket. Other

Fig. 9 (A) Representative ESI-MS spectrum of a solution containing 10
mM SARS-CoV-2 Mpro in water/acetonitrile (50 : 50) added with 0.1%
formic acid. The spectrum was acquired in positive ion mode. (B)
Representative ESI-MS spectrum of a mixture containing 10 mM SARSCoV-2 Mpro after incubation with QUB-00006-Int-07 (compound : protein ratio ¼ 10 : 1) in water/acetonitrile (50 : 50) added
with 0.1% formic acid. The spectrum was acquired in positive ion
mode. The red dots correspond to the unmodiﬁed protein, and the
green asterisks correspond to the modiﬁed protein.
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molecules were produced over the course of this research but,
due to their weaker activity, their detailed analysis is not
provided here. Their list can be found in the ESI.‡ These
compounds were either designed computationally without
leading to improved aﬃnities or were synthesis intermediates.
All resulting molecules were submitted to biological testing, but
none of them were found to be as potent as QUB-00006-Int-07
nor presented a strongly druggable prole, compared to the
previously discussed compounds.

5.

Conclusion and perspectives

We presented a computationally driven discovery of a new set of
non-covalent and covalent inhibitors of Mpro that have been
further characterized experimentally. The best compound,
QUB-00006-Int-07, has been found to be a covalent binder that
resulted in a potent inhibition of the Mpro enzymatic activity
(IC50 ¼ 830  50 nM). The results of the innovative scaﬀold
design described here were obtained within three months via
a fast-track project that took place in the summer of 2021. It
involved a small consortium of theoreticians, organic chemists
and drug designers, and demonstrated the eﬀectiveness of
a computation-guided synthetic strategy. Indeed, GPU-accelerated high-performance computing platforms can now provide
access to high-resolution molecular dynamics simulations,
which are able to predict detailed protein conformational maps
and provide accurate absolute binding free energy results. Such
computations can be further rationalized by means of adaptive
sampling simulations, an approach which is able to decipher
multiple binding modes. Coupled to NMR, in vitro experiments
and machine learning, such high-resolution predictions yield
structural insights regarding the design of new active
compounds, while oﬀering an atomic level understanding of
binding aﬃnities.
Beyond this preliminary proof of concept study, the next
research steps will be devoted to the QM/MM modeling78,79 of
the warhead reaction mechanism38,77,80 leading to the covalent
binding of QUB-00006-Int-07, and to optimization of active
compounds with the goal of reaching low nanomolar activity.
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